Mangoceuticals, Inc.
MGRX
$1.73
$0.074.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -40.48% | -39.51% | -15.80% | 52.24% | 245.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.48% | -39.51% | -15.80% | 52.24% | 245.65% |
| Cost of Revenue | -44.50% | -33.04% | -21.37% | 54.52% | 256.44% |
| Gross Profit | -37.59% | -43.51% | -11.94% | 50.61% | 238.07% |
| SG&A Expenses | 39.71% | 4.25% | -8.98% | 19.79% | 35.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.33% | 9.97% | 2.41% | 27.20% | 46.13% |
| Operating Income | -53.36% | -15.05% | -4.10% | -25.28% | -37.67% |
| Income Before Tax | -55.63% | -23.95% | 5.48% | -27.45% | -40.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.63% | -23.95% | 5.48% | -27.45% | -40.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 166.67% | -- | -- | -- | -- |
| Net Income | -55.63% | -23.94% | 5.49% | -27.43% | -40.11% |
| EBIT | -53.36% | -15.05% | -4.10% | -25.28% | -37.67% |
| EBITDA | -29.94% | -1.12% | 5.21% | -24.96% | -64.82% |
| EPS Basic | 43.87% | 38.64% | 46.44% | 27.43% | 16.50% |
| Normalized Basic EPS | 49.16% | 43.18% | 50.05% | 27.43% | 16.50% |
| EPS Diluted | 43.87% | 38.64% | 46.44% | 27.43% | 16.50% |
| Normalized Diluted EPS | 49.16% | 43.18% | 50.05% | 27.43% | 16.50% |
| Average Basic Shares Outstanding | 237.73% | 119.36% | 90.36% | 76.59% | 68.85% |
| Average Diluted Shares Outstanding | 237.73% | 119.36% | 90.36% | 76.59% | 68.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |